Use of topical ketanserin in the treatment of skin ulcers: a double-blind study.
The use of a 2% ointment formulation of ketanserin, an S2-serotoninergic blocking agent, was investigated in a randomized double-blind clinical trial for its effect on the healing of wounds of patients with decubitus, venous, and ischemic skin ulcers. The result demonstrates a significant difference in favor of the ketanserin-treated group (35 patients) versus the placebo-treated group (37 patients) on the basis of two factors: formation of granulation tissue and epithelialization. In addition, a significant difference of 150% in the initial velocity of wound closure was observed in favor of the patients treated with ketanserin. This effect was persistent during the entire study period.
Janssen
P A
PA
Janssen Research Foundation, Beerse, Belgium.
Janssen
H
H
Cauwenbergh
G
G
De Doncker
P
P
De Beule
K
K
Lewi
P
P
Tytgat
H F
HF
Lapière
C M
CM
D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007511:Ischemia; D007650:Ketanserin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D010919:Placebos; D003668:Pressure Ulcer / Q000188:drug therapy; D011897:Random Allocation; D012883:Skin Ulcer / Q000188:drug therapy* / Q000473:pathology; D014647:Varicose Ulcer / Q000188:drug therapy; D014945:Wound Healing
D010919:Placebos; D007650:Ketanserin